Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

46.51 -0.10 (-0.21%)

Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗

December 19, 2025

EXELIXIS INC (EXEL) combines strong fundamentals with a bullish technical setup. Its robust earnings growth, zero debt, and accelerating EPS align with a stock poised for a potential breakout.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗

December 15, 2025

Exelixis (EXEL) is a financially strong oncology biotech with high profitability, zero debt, and a low valuation relative to its earnings growth, fitting key value investing principles.

Via Chartmill

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

December 12, 2025

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Preview: Exelixis's Earnings ↗

November 03, 2025

Via Benzinga

Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation ↗

December 12, 2025

Exelixis (EXEL) exemplifies GARP investing with strong oncology earnings growth, a debt-free balance sheet, and a valuation discounted versus biotech peers.

Via Chartmill

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

December 03, 2025

From Exelixis, Inc.

Via Business Wire

2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗

December 01, 2025

These drugmakers are poised to profit from their innovative engines.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗

November 21, 2025

Discover EXELIXIS (EXEL), a value stock with strong profitability, zero debt, and solid growth, trading at an attractive discount to its industry peers.

Via Chartmill

Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗

November 19, 2025

Exelixis (EXEL) is a GARP stock with strong earnings growth, a reasonable valuation, and a debt-free balance sheet.

Via Chartmill

S&P 500 Surges as Congress Nears End to Protracted Government Shutdown

November 10, 2025

Washington D.C. – November 10, 2025 – Global financial markets are breathing a collective sigh of relief today as the S&P 500 index experiences a significant uplift, signaling investor optimism over...

Via MarketMinute

Topics Economy Regulatory Compliance Stocks

Global Markets Rally on Hopes for US Government Shutdown Resolution

November 10, 2025

Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government...

Via MarketMinute

Topics Bonds Economy Government

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

November 06, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

November 04, 2025

From Exelixis, Inc.

Via Business Wire

What's Driving the Market Sentiment Around Exelixis Inc? ↗

October 30, 2025

Via Benzinga

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗

October 28, 2025

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer.

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗

October 28, 2025

Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector.

Via Chartmill

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Exelixis, Inc.

Via Business Wire

This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 21, 2025

Via Benzinga

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Via Benzinga

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2025

Via Benzinga

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

October 20, 2025

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

October 18, 2025

From Exelixis, Inc.

Via Business Wire

The Ultimate Biotech Stock to Buy With $50 Right Now ↗

October 14, 2025

This innovative drugmaker still has plenty of upside potential.

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗

October 07, 2025

Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗

October 04, 2025

Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.